Background 2 Currently, the early pre-clinical detection of left ventricular (LV) dysfunction is difficult as 3 biomarkers are not specific for the cardiomyopathic process. The underlying molecular 4 mechanisms leading to heart failure remain elusive, highlighting the need for identification of 5 cardiac-specific markers. The growth hormone secretagogue receptor (GHSR) and its ligand 6 ghrelin are present in cardiac tissue and are known to contribute to myocardial energetics. Here, 7 we examined tissue ghrelin-GHSR levels as specific markers of cardiac dysfunction in patients 8 who underwent cardiac transplantation.
Introduction
previously used the far-red ghrelin analog probe (Ghrelin(1-18, Lys 18 (Cy5)) to quantify GHSR in 1 situ 4 . This analog binds with high specificity to GHSR in mouse cardiac tissue samples 6 . 2 Therefore, we used Ghrelin(1-18, Lys 18 (Cy5) to quantify the expression of GHSR. Following 3 incubation with secondary antibodies, this probe was added to tissue sections for 30 min and used 4 for GHSR detection. Sections were washed with PBS, incubated 8 min with DAPI nuclear stain 5 (1:1000), and mounted with ProLong Gold antifade (Life Technologies) to prevent the tissues from 6 photobleaching. Images were captured with a Nikon Eclipse TE2000-S fluorescent microscope. 7 Five random fields of view were acquired for each of 4 tissue sections at 20X magnification (Nikon 8 NIS Elements v. BR 4.50.00). software. Fluorescence microscopy was also used to acquire collagen I images as described above. section was quantified using a custom FIJI script that integrates raw density images that represent 10 protein expression levels, as previously reported by us 4, 14 . Briefly, thresholding was conducted for 11 each image to determine the fluorescence intensity (positive pixel count above threshold minus the 12 background). Fibrosis was analyzed using an online script which quantified the percentage of 13 fibrotic tissue in each sample by distinguishing fibrotic tissue from non-fibrotic tissue 15 3. Results 22 
Cardiac transplant patient cohort
Sixty percent of the patients who underwent cardiac transplantation were male, with an overall 1 mean age of 54 years ( Table 2) . Fifty percent had significant coronary artery disease pre-transplant, 2 and none had diabetes. All patients had elevated pulmonary artery pressures pre-transplant, along 3 with severely reduced left ventricular ejection fraction (LVEF <30%) by echocardiographic 4 assessment. Serial echocardiographic assessment of LV function following cardiac transplant 5 showed LV recovery to an LVEF > 50% in 80% of patients by 1 month PTx. By 6 months PTx, 6 all patients had normal LV function ( Table 2) . Although most patients were receiving HF 7 medications, i.e., angiotensin converting enzyme (ACE) inhibitors/beta blockers/diuretics, prior to 8 transplantation, only a small number continued to receive these medications following surgery.
9 Table 3 contains a complete listing of medications pre-and post-Tx. highly significant positive correlation with the level of ghrelin expression (r = 0.7817, p<0.0001). 17 To examine associations of ghrelin and GHSR with cardiac dysfunction, data were divided into 2 was examined for colocalization between collagen I and GHSR by fluorescence microscopy 21 ( Figure 5 A and B) . These analyses showed no colocalization between collagen I and GHSR in the 
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